SSRI / SNRI Class Drugs

Paroxetine Seroxat Paxil ~ Citalopram Cipramil Celexa ~ Fluvoxamine Faverin Luvox ~ Escitalopram Cipralex Lexapro
~ Fluoxetine Prozac Sarafem ~ Sertraline Lustral Zoloft ~ Venlafaxine Efexor Effexor ~ Duloxetine Cymbalta Yentreve

Thursday, 7 May 2009

Prescription & Increase Totals

Click image to enlarge
http://farm4.static.flickr.com/3331/3492055975_b1ef73c293_o.jpg

The obvious 2004 to 2005 marginal trends reversal of Total Annual Prescription Increases correlates with: -

1 The “Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitors (SSRIs)” published December 2004
http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf

2 The "House of Commons, Health Committee’s examination into The Influence of the Pharmaceutical Industry" - initiated June 2004 - report published April 5th 2005
http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf


****
Data collection reference:
Department of Health; NHS; Prescription Cost Analysis (PCA) - England.
1998 to 2007:
http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2008:
http://www.ic.nhs.uk/webfiles/publications/PCA%202008/PCA%202008.pdf
P-3 Tuesday



No comments:

Post a Comment